OncoMatch/Clinical Trials/NCT04197297
Brain Imaging Biomarkers in Patients With Brain Metastasis
Is NCT04197297 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for brain metastases, adult.
A biomarker is a measurable indicator of the severity or presence of some disease state. In this study, brain metastases patients who will be receiving radiation treatment, will undergo CT (Computed Tomography) and MRI (Magnetic Resonance Imaging) scans prior to and after radiation treatment to measure these biomarkers. This is a single-center phase II study to validate the predictive abilities of biomarkers, in terms of determining how patients will respond to radiation treatment.
Check if I qualifyExtracted eligibility criteria
Disease stage
Metastatic disease required
Prior therapy
Cannot have received: whole brain radiotherapy
Previous Whole Brain Radiotherapy
Cannot have received: radiosurgery to the index lesion
Previous radiosurgery to the index lesion
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04197297 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior whole brain radiotherapy, radiosurgery to the index lesion disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify